Open AccessAntibody markers in the diagnosis of inflammatory bowel disease
Author(s) -
Keiichi Mitsuyama,
Masao Niwa,
Hidetoshi Takedatsu,
Hiroshi Yamasaki,
Kotaro Kuwaki,
Shinichiro Yoshioka,
Ryosuke Yamauchi,
Shuji Fukunaga,
Takuji Torimura
Publication year - 2016
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v22.i3.1304
Subject(s) - medicine , ulcerative colitis , inflammatory bowel disease , autoantibody , etiology , antibody , inflammatory bowel diseases , crohn's disease , disease , immunology , gastroenterology , pathology
Inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, is a chronic intestinal inflammation of unknown etiology. The diagnosis of IBD is based on endoscopic, radiologic and histopathologic criteria. Recently, the search for a noninvasive marker that could augment or replace part of this diagnostic process has become a focus of IBD research. In this review, antibody markers, including microbial antibodies, autoantibodies and peptide antibodies, will be described, focusing on their common features. At present, no single marker with qualities that are satisfactory for the diagnosis and treatment of IBD has been identified, although panels of some antibodies are being evaluated with keen interest. The discovery of novel IBD-specific and sensitive markers is anticipated. Such markers could minimize the use of endoscopic and radiologic examinations and could enable clinicians to implement individualized treatment plans designed to improve the long-term prognosis of patients with IBD.